{"a":[{"_":"Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea","$":{"href":"/pharma/astrazeneca-bristol-myers-squibb-merger-would-be-bad-idea","hreflang":"en"}}]}

Summary

An editorial argues that a proposed merger between AstraZeneca and Bristol Myers Squibb would create severe regulatory concerns, pipeline disruptions, job losses, and harm to the broader biopharma ecosystem and patients.